Studies have shown that active fund managers routinely underperform the S&P500 index*​

Immuneering Corporation (NASDAQ: IMRX)

IMRX Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
284.10%

IMRX Stock Analysis

IMRX PE Ratio:

IMRX PEG Ratio: Not Available

IMRX Forward EPS Growth (12 month): 0.00%

IMRX PS Ratio:

IMRX PSG Ratio: Not Available

IMRX Forward Revenue Growth (12 month): 0.00%

IMRX Articles

No data was found